KTTA stock forecast, quote, news & analysis
Pasithea Therapeutics Corp is a biotechnology company... Show more
Why Pasithea Therapeutics (KTTA) Stock Is Down -25% in the Last 30 Days
Key Takeaways
- KTTA shares fell roughly 25% over the last 30 days, sliding from about $0.49 to around $0.37 on a closing basis.
- The decline extends a broader multi-month downtrend, with the stock down approximately 19% over the trailing quarter.
- Shareholder approval of a reverse stock split (1-for-2 to 1-for-20) at the September 9 annual meeting weighed on sentiment amid Nasdaq minimum-bid-price concerns.
- As a thinly traded, sub-$1 micro-cap biotechnology company, KTTA remains prone to outsized price swings on relatively modest trading volume.
- Positive clinical momentum — including April 2026 FDA Fast Track and Rare Pediatric Disease designations for PAS-004 — has not halted the slide.
- The first public disclosure of PAS-004 NF1 clinical data, set for the European Neurofibromatosis Conference in November, is a key upcoming catalyst.
- For additional detail, explore Pasithea Therapeutics' Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots for AI-driven trading insights across thousands of tickers.
Pasithea Therapeutics (KTTA) Company Overview and Market Position
Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a clinical-stage biotechnology company headquartered in Miami, Florida, focused on developing treatments for RASopathies, MAPK pathway-driven tumors, and other diseases. Its lead candidate, PAS-004, is a next-generation macrocyclic oral MEK inhibitor being evaluated for neurofibromatosis type 1 (NF1)-associated neurofibromas and for advanced cancers. The company is currently running a Phase 1 trial in advanced cancer patients and a Phase 1/1b trial in adult patients with NF1-associated plexiform neurofibromas. PAS-004 has received FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Investors follow KTTA primarily for the clinical progress of PAS-004 and the potential to become the first systemic therapy approved for certain NF1 manifestations, a market with substantial unmet need.
Pasithea Therapeutics (KTTA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, KTTA shares declined from a closing price of $0.4930 on September 30 to $0.3702 on October 30, a drop of approximately 24.9%. The move was not a single-session collapse but a steady grind lower punctuated by brief rebounds, with elevated volume on several down days.
The last quarter tells a similar story. From roughly $0.46 at the end of July to about $0.37 in late October, the stock lost approximately 19%. This extends a persistent downtrend that has kept the shares trading well below the $1.00 threshold, reflecting sustained selling pressure, low liquidity, and lingering uncertainty about the company's share structure and Nasdaq listing compliance.
What Drove KTTA Stock Price in the Last 30 Days
The most significant structural event was the September 9 annual meeting, where shareholders approved a reverse stock split at a flexible ratio ranging from 1-for-2 to 1-for-20, with the exact ratio left to the board's discretion. Because the company has traded below $1.00 for an extended period, the authorization is widely viewed as a measure to address Nasdaq's minimum-bid-price requirement. Such proposals are often interpreted by the market as a sign of financial distress and can pressure a stock lower, and KTTA continued to slide through September and October.
Beyond the reverse split, the decline reflects the broader characteristics of an early-stage, thinly capitalized biotech. With a modest market capitalization and relatively low average daily liquidity, KTTA is susceptible to sharp moves on comparatively small order flow. Absent a fresh positive clinical catalyst in October, the shares drifted lower as risk appetite for speculative micro-cap names weakened.
What Drove KTTA Stock Performance Over the Last Quarter
The quarterly decline sits in contrast to a run of otherwise constructive clinical news. In April 2026, the FDA granted Fast Track and Rare Pediatric Disease designations to PAS-004 for NF1-associated plexiform neurofibromas. In late June, the company reported positive interim Phase 1 data in advanced cancer patients, highlighting a differentiated safety profile and durable clinical activity. Despite these milestones, the shares could not hold gains.
The dominant narrative over the quarter was one of share-price pressure rather than clinical setbacks. Investor concerns centered on the sub-$1 share price, the reverse stock split authorization, potential future dilution as the company funds development through capital markets, and general caution toward pre-revenue micro-cap biotechs. These factors outweighed the company's regulatory and data momentum during the period.
Trending AI Robots
For traders seeking a systematic perspective on market moves, Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots. Tickeron operates hundreds of AI trading bots that monitor thousands of tickers, but only top-performing and most relevant bots appear in this curated section. The bots vary in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than rely on a single model. The page is designed to surface the strategies currently gaining traction in the market. Investors and traders interested in complementing their own analysis with data-driven, rule-based signals can explore the section to see which AI strategies are trending.
KTTA Stock Forecast Drivers: What Investors Should Watch Next
The clearest near-term catalyst is the initial PAS-004 clinical data presentation at the 2026 European Neurofibromatosis Conference, scheduled for November 12-14 in Vienna. This represents the company's first public disclosure of Part A data from its Phase 1/1b NF1 trial, covering safety, tolerability, pharmacokinetics, and early efficacy signals. Management has also indicated dose selection for a potential expansion cohort targeted around the first or second quarter of the following year.
Investors should also monitor whether and when the board implements the authorized reverse stock split and at what ratio, as well as the company's Nasdaq listing compliance status. Cash runway and any associated financing or dilution events remain key considerations for a pre-revenue developer. Finally, broader risk appetite for micro-cap biotechnology, FDA regulatory developments, and additional PAS-004 data readouts will continue to shape the stock's trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KTTA in downward trend: price dove below 50-day moving average on September 25, 2026
KTTA moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend. In 41 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KTTA as a result. In 82 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for KTTA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 39 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
The 10-day moving average for KTTA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KTTA entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KTTA's RSI Oscillator exited the oversold zone, 37 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
KTTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.248) is normal, around the industry mean (3.162). P/E Ratio (-0.274) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. KTTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology